TYRA-200 represents a next-generation covalent inhibitor specifically engineered to target FGFR2, addressing critical limitations in current therapeutic options. The fibroblast growth factor receptor 2 plays pivotal roles in cellular proliferation and differentiation, with its genetic alterations strongly implicated in intrahepatic cholangiocarcinoma (iCCA) pathogenesis - particularly the FGFR2 fusions observed in 10-15% of iCCA cases. While pan-FGFR inhibitors have recently emerged as treatment options for advanced biliary tract cancers, their clinical utility is frequently compromised by polyclonal resistance mutations, predominantly within the FGFR2 kinase domain. TYRA-200 was developed through structure-guided rational design to overcome these resistance mechanisms.

Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.